Highly efficient in situ cell purification method based on synthetic mRNA switch(s) and a synthetic peptide
Patent Information
- Application Number
- PCT/IB2024/000077
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-06
- Filing Date
- 2024-02-06
- Publication Date
- 2024-11-07
AI Technical Summary
Current cell purification methods, such as magnetic bead-based and fluorescence-activated cell sorting, face limitations in availability of cell-type specific surface antigens and require conversion of attached cells to suspension, leading to poor recovery and limited general applicability, especially for stem cells where differentiation is not 100% successful.
A novel method using synthetic mRNA switches encoding cell surface alkaline phosphatase linked to cytosolic markers, combined with a phosphorylated D-amino acid peptide that forms a nanonet/hydrogel around non-target cells, allowing for high-purity and high-recovery cell purification without the need for specific marker molecule consideration.
This method effectively distinguishes and eliminates non-target cells, including stem cells, achieving high purity and recovery of target cells, and can be used for sensing different cytosolic marker molecules, eliminating cells with or without markers, and purifying multiple cell types simultaneously.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] HIGHLY EFFICIENT IN SITU CELL PURIFICATION METHOD BASED ON SYNTHETIC MRNA SWITCH(S) AND A SYNTHETIC PEPTIDE
[0002] CROSS-REFERENCE TO RELATED APPLICATION
[0003] The subject application claims the benefit of U.S. Provisional Application Serial No. 63 / 483,519, filed February 6, 2023, which is incorporated herein by reference in its entirety.
[0004] SEQUENCE LISTING
[0005] The Sequence Listing for this application is labeled “HKUS187XPCT.xml” which was created on February 5, 2024 and is 8,662 bytes. The entire contents of the sequence listing is incorporated herein by reference in its entirety.
[0006] BACKGROUND OF THE INVENTION
[0007] Cell purification describes the process of separating unwanted cells from a biological sample to eliminate external influences on downstream results. It is an important method to help scientists study specific cell types. Biological samples often contain multiple cell types at different stages in their development processes and these unwanted or off-target cells can have negative impacts in scientific analyses.
[0008] With the development of stem cell technologies, especially the induced pluripotent stem cells (iPSCs) technologies, differentiated cells generated from stem cells offer previously unattainable sources of cells for various purposes, including but not limited to disease modelling, cell therapy, tissue engineering, personalized drug screening. However, one hurdle for application of the purity of the target cells. Stem cells differentiation is rarely 100% successful: undifferentiated stem cells can exist; wrong type of cells can be generated.
[0009] There are a variety of methods of purify cell samples, but the two most popular are magnetic bead-based cell sorting and fluorescence-activated cell sorting. Currently, competing products and services to purify cells mainly focus on the use of an antibody for cell recognition. While the method can effectively purify cells based on a cell type specific surface antigen, such methods are limited on the availability of a cell type specific surface antigen and the requirement to convert attached cells into a suspension that damages the target cell, leading to a poor recovery. Existing in situ methods include chemical- or peptide- based in situ cell purification and synthetic mRNA switch-based in situ cell purification. The chemical- or peptide-based methods are tailored only to target specific cells, lacking general applicability. The synthetic mRNA switch-based purifications have a low recovery rate on the target cells and require additional consideration to eliminate stem cells. Thus, novel methods are needed for more efficient in situ cell purification.
[0010] BRIEF SUMMARY OF THE INVENTION
[0011] The subject invention pertains to a cell purification method. The method uses novel synthetic mRNA switches and at least one synthetic peptide. In certain embodiments, the synthetic mRNA switch can encode a cell surface alkaline phosphatase sequence operably linked to a sequence targeting cytosolic cell type marker molecule. In certain embodiments, the synthetic peptide is a phosphorylated D-amino acid formed peptide with N terminus modified with aromatic rings.
[0012] In certain embodiments, the synthetic mRNA switch can be introduced to a cell. In certain embodiments, the switch can distinguish target cells from non-target cells based on the difference in the level of the cytosolic cell type marker molecules. In certain embodiments, the alkaline phosphatase can be expressed only on the non-target cell surface. In certain embodiments, after switch introduction, a synthetic peptide can be added into culture media containing the cell. In certain embodiments, the alkaline phosphatase triggers the dephosphorylation of the synthetic peptide. In certain embodiments, when the alkaline phosphatase is highly expressed, the dephosphorylation rate is high.
[0013] In certain embodiments, self-assembly of the dephosphorylated synthetic peptide can form a nanonet / hydrogel around the surface of the cells to induce viability loss of these cells. In certain embodiments, when leaky alkaline phosphatase expression happens, the dephosphorylation rate is low. “Leaky expression” means basal level ALP expression when the translation of the mRNA is suppressed. In certain embodiments, the dephosphorylated synthetic peptide can diffuse into media and the cells will not be damaged.
[0014] Stem cells naturally express alkaline phosphatase on the surface; therefore, in certain embodiments, the subject methods can be used to remove stem cells. In certain embodiments, the removal of stem cells prevents stem-cell caused tumor generation or colony formation and also reduces the difficulty level for selecting a marker molecule. In certain embodiments, there is no need to consider the marker molecule level in stem cells. In certain embodiments, the subject methods yield a high purity and high recovery of target cells. In certain embodiments, the method can be used for sensing different cytosolic marker molecules; for sensing one or more molecules; for eliminating cells with or without cytosolic marker molecules; and for purifying one or two types of cells at the same time.
[0015] BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0017] FIGs. 1A-1B. FIG. 1A The scheme of the subject cell purification method. FIG. IB The chemical structures of the peptides synthesized.
[0018] FIGs. 2A-2B. FIG. 2A Alkaline phosphatase activities of HEK293 at 24 hours posttransfection of different amounts of ALP mRNA and 201B7 without transfection. FIG. 2B The viability of HEK293 cells 24 hours after peptide treatment with or without transfection with ALP mRNA (n =3; data presented at mean ± standard deviation).
[0019] FIG. 3. Observation of ALP triggered nanonet / hydrogel formation by the peptides. The HEK293 cells were transfected with or without ALP encoding mRNA. On the next day, the cells were incubated with peptides at 500 pM at 37°C for 2 hours, the dishes were placed in a 4°C room for 5 min. The dishes were tilted and agitated to collect the detached nanonets / hydrogels in media. Using a wide mouth transfer pipette, the media were collected into 1.5 mL Eppendorf tubes and centrifuged at 7500 rpm for 1 minutes to reveal the nanonets / hydrogels at the bottom of the tubes.
[0020] FIGs. 4A-4E. FIG. 4A Illustration of miR-21-ALP switch and miR-21-Bim switch. FIG. 4B Relative viability of HEK293 cells 24 hours post-treatment with miR-21-ALP + D3 or miR-21-Bim, co-transfected with different amount of microRNA-21 mimic. FIG. 4C Relative viability of HEK293, MDA-MB-231 and HepG2 cells 24 hours post-treatment with miR-21-ALP + D3 or miR-21-Bim (FIGs. 4D-4E) Co-culture of HEK293-CFP, MDA-MB- 231 and HepG2-RFP treated by miR-21-ALP + D3 or miR-21-Bim. FIG. 4D Relative cell number of each cell line. FIG. 4E Representative flow cytometry dot plot graph (n =3; data presented at mean ± standard deviation).
[0021] FIG. 5. Illustration of miR-21-ALP switch, miR-IDT-ALP switch, and miR-21 / IDT- ALP switch. Relative viability of HEK293 cells 24 hours post-treatment with D3. 24 hours before D3 treatment, the cells are transfected with miR-21-ALP switch, miR-IDT-ALP switch, miR-21 / IDT-ALP switch, and miR-21-ALP+ miR-IDT-ALP switch, co-transfected with microRNA-21 mimic, microRNA-IDT mimic, microRNA-21+microRNA-IDT mimic or without mimic (n =3; data presented at mean ± standard deviation).
[0022] FIGs. 6A-6D. FIG. 6A Illustration of neuron cell differentiation. FIG. 6B Relative viability of 201B7, Neuron and 201B7dl4 cells 24 hours post-treatment with miR-31-ALP + D3, ALP mRNA + D3 or D3 only (FIGs. 6C-6D) Co-culture of 201B7, Neuron and 201B7dl4 cells. FIG. 6C Representative flow cytometry analysis of the co-culture 24 hours post-treatment, cells are stained with anti-Nestin or anti-Oct3 / 4 antibody FIG. 6D co-culture 7 days after treatment, ALP were stained (n =3; data presented at mean ± standard deviation).
[0023] FIG. 7. MCP protein-sensing ALP-encoding mRNA switch with D-3 peptide treatment can efficiently eliminate cells expressing MCP proteins. Cells without MCP protein expression have little-to-no cell loss. The cell purification performance is much better than the MCP protein-sensing Bim-encoding mRNA switch, (n =3; data presented at mean ± standard deviation).
[0024] BRIEF DESCRIPTION OF THE SEQUENCES
[0025] SEQ ID NO: 1: 5 -UTR
[0026] SEQ ID NO: 2: 4xanti-miR-21-5'-UTR
[0027] SEQ ID NO: 3: 4xanti-IDT-5'-UTR
[0028] SEQ ID NO: 4: 2xanti-31-5'-UTR
[0029] SEQ ID NO: 5: 2xanti-miR-132-5'-UTR
[0030] SEQ ID NO: 6: 2xMS2-5’UTR
[0031] SEQ ID NO: 7: 3 -UTR
[0032] SEQ ID NO: 8: 4xanti-miR-21-3’-UTR
[0033] DETAILED DISCLOSURE OF THE INVENTION
[0034] Selected Definitions
[0035] As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and / or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising”. The transitional terms / phrases (and any grammatical variations thereof) “comprising”, “comprises”, “comprise”, “consisting essentially of’, “consists essentially of’, “consisting” and “consists” can be used interchangeably.
[0036] The term “about” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured, z.e., the limitations of the measurement system. In the context of compositions containing amounts of ingredients where the term “about” is used, these compositions contain the stated amount of the ingredient with a variation (error range) of 0-10% around the value (X ± 10%). In other contexts, the term “about” is providing a variation (error range) of 0- 10% around a given value (X ± 10%). As is apparent, this variation represents a range that is up to 10% above or below a given value, for example, X ± 1%, X ± 2%, X ± 3%, X ± 4%, X ± 5%, X ± 6%, X ± 7%, X ± 8%, X ± 9%, or X ± 10%.
[0037] In the present disclosure, ranges are stated in shorthand to avoid having to set out at length and describe each and every value within the range. Any appropriate value within the range can be selected, where appropriate, as the upper value, lower value, or the terminus of the range. For example, a range of 0.1-1.0 represents the terminal values of 0.1 and 1.0, as well as the intermediate values of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and all intermediate ranges encompassed within 0.1-1.0, such as 0.2-0.5, 0.2-0.8, 0.7-1.0, etc. Values having at least two significant digits within a range are envisioned, for example, a range of 5-10 indicates all the values between 5.0 and 10.0 as well as between 5.00 and 10.00 including the terminal values. When ranges are used herein, combinations and subcombinations of ranges (e.g., subranges within the disclosed range) and specific embodiments therein are explicitly included.
[0038] In this application, the terms “peptide”, and “protein” are used interchangeably herein to refer to a polymer of amino acids. The terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of corresponding naturally occurring amino acids, as well as to naturally occurring amino acid polymers and non- naturally occurring amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full-length proteins, wherein the amino acid residues are linked by covalent peptide bonds.
[0039] As used herein, the term “amino acid” refers to standard nomenclature, amino acid residue as denominated by either a three letter or a single letter code as indicated as follows: Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cysteine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (He, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine (Vai, V).
[0040] As used herein, the term “nucleic acid” or “polynucleotide” refers to deoxyribonucleic acids (DNA) or ribonucleic acids (RNA) and polymers thereof in either single- or doublestranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs), and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.
[0041] As used herein, the terms “identical” or percent “identity”, in the context of describing two or more polynucleotide or amino acid sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (for example, a nucleotide probe used in the method of this invention has at least 70% sequence identity, preferably 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity, to a target sequence or complementary sequence thereof), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be “substantially identical”. With regard to polynucleotide sequences, this definition also refers to the complement of a test sequence.
[0042] A nucleotide sequence is referred to as “operably linked” when it is placed into a functional relationship with another nucleotide segment (for example, an mRNA sequence encoding a cell surface alkaline phosphatase linked to a nucleotide sequence targeting a cytosolic cell type marker molecule). Two or more operably linked nucleotide sequences can be separated by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, about 25, about 30, about 45, about 50, about 75, about 100, about 150, or more nucleotides. Linking can be accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
[0043] By “reduces” is meant a negative alteration of at least 1%, 5%, 10%, 25%, 50%, 75%, or 100%.
[0044] By “increases” is meant as a positive alteration of at least 1%, 5%, 10%, 25%, 50%, 75%, or 100%.
[0045] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
[0046] Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
[0047] All references cited herein are hereby incorporated by reference in their entirety.
[0048] Method of Cell Purification
[0049] The subject invention pertains to a cell purification method. The method uses novel synthetic mRNA switches of from about 1600 to about 3000 nucleotides in length and at least one synthetic peptide. In certain embodiments, the synthetic mRNA switch can encode a cell surface placental alkaline phosphatase sequence (NCBI Reference Sequence: NP 001623.3) operably linked to a sequence targeting cytosolic cell type marker molecule or an mRNA sequence encoding a cell surface alkaline phosphatase operably linked to a nucleotide sequence targeting a viral coat protein and an mRNA sequence encoding a viral coat protein operably linked to a nucleotide sequence targeting a cytosolic cell type marker molecule. In certain embodiments, the mRNA switch is an RNA oligonucleotide. In certain embodiments, the cytosolic cell type marker molecule is a microRNA (miR), preferably a high expressing miRNA selected from those well-known in the art, as can be found, for example, at miRbase (https: / / mirbase.org). In certain embodiments, the miR is miR-31, miR-21, or miR-132. In certain embodiments, the RNA binding protein is bacteriophage MS2 coat protein (MCP), L7Ae (Uniplot: Q8U160), or PP7 coat protein (NP 042305.1). In certain embodiments, the sequence encoding the cell surface alkaline phosphatase sequence is separated from the sequence targeting cytosolic cell type marker molecule or the sequence targeting RNA binding protein by at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, about 25, about 30, about 45, about 50, about 75, about 100, about 150, or more nucleotides. In certain embodiments, the synthetic peptide is a phosphorylated D-amino acid formed peptide with N terminus modified with aromatic rings. In certain embodiments, the phosphorylated D-amino acid formed peptide with an N terminus modified with an aromatic ring is D-l (Formula (I)), D-2 (Formula (II)), D-3 (Formula (III)), D-4 (Formula (IV)), D-5 (Formula (V)), D-6 (Formula (VI)), D-7 (Formula (VII)), or D-8 (Formula (VIII)):
[0050] Formula (I) Formula (II) Formula (III)
[0051] Formula (IV)
[0052] Formula (V) Formula (VI) In preferred embodiments, the phosphorylated D-amino acid formed peptide with an N terminus modified with an aromatic ring is D-3 (Formula (III)). In certain embodiments, the synthetic mRNA switch can be introduced to a cell, preferably at a concentration of at least 200pM. In certain embodiments, the switch can distinguish target cells from non-target cells based on the difference in the level of the cytosolic cell type marker molecules. In certain embodiments, the alkaline phosphatase can be expressed only on the non-target cell surface. In certain embodiments, after switch introduction, a synthetic peptide can be added into culture media containing the cell, preferably at a concentration of at least 200pM. In certain embodiments, the alkaline phosphatase triggers the dephosphorylation of the synthetic peptide. In certain embodiments, when the alkaline phosphatase is highly expressed, the dephosphorylation rate is high. In certain embodiments, the target cell type is a neuron. The non-target cell type is any cell type without the miRNA of the target. In certain embodiments, the non-target cell type is a stem cell.
[0053] In certain embodiments, self-assembly of the dephosphorylated synthetic peptide can form a nanonet / hydrogel around the surface of the non-target cells to induce viability loss of these non-target cells. In certain embodiments, when leaky alkaline phosphatase expression happens, the dephosphorylation rate is low. In certain embodiments, the dephosphorylated synthetic peptide can diffuse into media and the cells will not be damaged.
[0054] Stem cells naturally express alkaline phosphatase on the surface; therefore, in certain embodiments, the subject methods can be used to remove stem cells. In certain embodiments, the removal of stem cells prevents stem-cell caused tumor generation or colony formation and also reduces the difficulty level for selecting a marker molecule. In certain embodiments, there is no need to consider the marker molecule level in stem cells.
[0055] In certain embodiments, the subject methods yield a high purity and high recovery of target cells. In certain embodiments, the method can be used for sensing different cytosolic marker molecules; for sensing one or more molecules; for eliminating cells with or without cytosolic marker molecules; and for purifying one or two types of cells at the same time.
[0056] This invention describes a method for in situ cell purification, which comprises the following steps:
[0057] Introducing into the cell a mRNA with a sequence encoding cell surface alkaline phosphatase operably linked to a sequence targeting cytosolic cell type marker molecule(s); or introducing into the cell a mRNA with a sequence encoding cell surface alkaline phosphatase operably linked to a sequence targeting a viral coat protein and a mRNA with a sequence encoding a viral coat protein operably linked to a sequence targeting cytosolic cell type marker molecule(s); and incubating the cells in culture media containing a phosphorylated D-amino acid formed peptide with N terminus modified with aromatic rings.
[0058] In certain embodiments, the non-target cell is a stem cell. In certain embodiments, at least about 75%, about 80%, about 85%, about 90%, about 95%, about 97.5%, about 99%, about 99.9%, about 99.99% of the non-target cells are eliminated.
[0059] MATERIALS AND METHODS
[0060] Table 1 shows the nucleotide sequences of UTRs used in all the samples. All the UTR sequences were incorporated into the DNA templates encoding for alkaline phosphatase (ALP), bcl-2 interacting mediator of cell death (Bim), puromycin resistant gene (PuroR), enhanced green fluorescent protein (EGFP) or bacteriophage MS2 coat protein (MCP) using PCR (Q5® High-Fidelity 2X Master Mix). The purified PCR products were directly used for in vitro synthesis of mRNAs using MEGAscript™ T7 Transcription Kit (Invitrogen (Carlsbad, California, USA)). The mRNAs were synthesized with adenosine triphosphate, cytidine triphosphate, N1methylpseudouridine-5’ -triphosphate, guanosine triphosphate and Anti Reverse Cap Analog (TriLink BioTechnologies (San Diego, California, USA)) with a molar ratio at 5:5:5: 1 :4. All peptides (FIGs. 1A-1B) were synthesized by standard solidphase peptide synthesis. All the cells are cultured and passaged using standard media and standard Trypsin protocol. Lipofectamine™ MessengerMax™ (Therm ofisher(Waltham, Massachusetts, USA)) was used for all the transfections of mRNAs, following the manufacturer’s protocol. For all transfection, 90 nM of PuroR mRNA was co-transfected for positively transfected cell selection. The positively transfected cells were selected by addition of puromycin to a final concentration of 4 ug / mL at 4 hours post-transfection. Positively transfected cells selection was performed in all experiments. All peptide treatment was performed by first dissolving peptide in water and NaOH to 10 mM. The peptide solution was diluted in culture medium at final concentration of 500 pM. Cell culture medium was replaced by D-3 containing medium for 2 hours. After 2 hours incubation, medium was replaced by fresh culture medium and further incubate for another 22 hours before further analysis. Table 1. UTR sequences and the sample that contained the sequences. All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
[0061] Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
[0062] EXAMPLE 1— THE CELL PURIFICATION METHOD CAN EFFICIENTLY ELIMINATE CELLS
[0063] HEK293 and 201B7 cells were seeded in 24-well plate 24 hours before transfection at 0.5 x 105cells / well. HEK293 were transfected with 90, 170, 260, 340, 430, 510, 600, 680, 770 or 860 nM of ALP mRNA and co-transfected with 90 nM PuroR mRNA for positively transfected cells selection. At 24 hours post-transfection, cell lysates were collected using CelLytic M (Sigma- Aldrich) following manufacturer’s protocol. The ALP activities were determined by alkaline phosphatase assay kit (Abeam (Cambridge, United Kingdom)) following manufacturer’s protocol. For comparison of peptide, HEK293 were transfected with 600 nM of ALP mRNA and co-transfected with 90 nM PuroR mRNA for positively transfected cells selection. At 24 hours post-transfection, peptide treatment, described in method, of D-l, D-2, D-3, D-4, D-5, D-6, D-7, D-8, or D-9 was performed. MTT based cell viability assay was performed following manufacturer’s protocol.
[0064] We optimized the mRNA concentration and type of peptide for cell purification. We synthesized a series phosphate group conjugated peptides (FIGs. 1A-1B). To determine the concentration for the following tests, we transfected HEK293 cells with increasing amount of ALP mRNA. The ALP activities increased with the amount of mRNA transfected (FIG. 2A). We observed that the ALP activities plateaued above 510 nM mRNA transfected with ALP activity of around 70 mU / ng which is comparable to high ALP activity cell 201B7.
[0065] Next, we treated the cell transfected with 600 nM ALP mRNAs with the series of peptides. Among the peptides tested, D-3 was the most efficient in cell removal with <10% cell viability by MTT assay (FIG. 2B). In addition, the cell viability retained at 100% when the cells were not transfected with ALP mRNA. This showed that the peptide without ALP did not induce any toxic effect, which is ideal for cell purification with increased yield. EXAMPLE 2— THE CELL PURIFICATION METHOD IS HIGHLY SENSITIVE TO MICRORNA
[0066] In a microRNA sensing experiment, HEK293, MDA-MB-231 and HepG2 cells were seeded in 24-well plate 24 hours before transfection at 0.5 x 105cells / well. For co-culture experiment, HEK293-CFP, MDA-MB-231 and HepG2-RFP were seeded in 6-well plate 24 hours before transfection at 1 x 105, 2 x 105and 2 x 105cells / well respectively. All cells were transfected with 600nM of miR-21-ALP or miR-21-Bim, and co-transfected with 90 nM PuroR mRNA for positively transfected cells selection. At 24 hours post-transfection, peptide treatment with D-3 peptide was performed for cells transfected by ALP mRNA. After that, MTT based cell viability assay was performed following manufacturer’s protocol. For coculture experiment, the cells were resuspended in culture medium with trypsin and analysis by flow cytometry with BD FACSAria III (BD biosciences (Franklin Lakes, New lersey, USA)).
[0067] We synthesized two mRNA switches that expressed ALP and Bim respectively (FIG. 4A). The Bim protein is a cytotoxic protein and Bim expressing synthetic mRNA switches are previously described methods for cell purification. Both of the switches were designed to sense microRNA-21 to reduce protein expression level. We first compared the performance of both switches with increasing amount of artificial microRNA-21 mimic. We observed that the viability of cells treated with miR-21-ALP switch + D-3 reached above 80% at 1 nM mimic, while that of the cells treated with miR-21-Bim switch remained around 50% even at 4 nM mimic (FIG. 4B). This showed that the miR-21-ALP switch +D-3 is more sensitive to low microRNA concentration as shown in the increase of viability at low mimic concentration.
[0068] Next, we compared response of the two group on endogenous microRNA activities. We treated the two group on 3 different cell lines: HEK293 with low microRNA-21 activity, MDA-MB-231 and HepG2 with high microRNA-21 activity. As shown in FIG. 4C, HEK293 was effectively removed in both group while the viability of MD A-MB-231 and HepG2 was only recovered in miR-21-ALP switch + D3 group. In miR-21-Bim group, the viability for MD A-MB-231 remained below 20% and the viability for HepG2 could only recover up to 70%. This further provide evidence for miR-21-ALP switch + D3 being more sensitive on microRNA. Finally, we compared the performance of selective cell removal the two group in coculture condition to mimic practical application. To visualize the cell population, we used fluorescent expressing cell line: HEK293-CFP and HepG2-RFP. The results are shown in FIG. 4D and FIG. 3E, relative cell number are represented by the percentage cell count of the treated group to the untreated control group. For miR-21-ALP + D3 group, effective removal of HEK293-CFP can be observed, while the other 2 high microRNA-21 cell lines has >90% relative cell counts. For miR-21-Bim group, not only significant loss of the 2 high microRNA-21 cell lines can be observed, notable amount of HEK293-CFP can also be observed in the dot plot.
[0069] EXAMPLE 3— MULTI-SIGNAL AMPLIFICATION MINIMIZES LEAKY EXPRESSION EFFECT
[0070] As shown in previous section, the cells treated with miR-21-Bim switch remained at low cell viability even at high artificial mimic concentration, and in high microRNA-21 activity cell lines. This might suggest leaky expression of cytotoxic protein. For the miR-21- ALP + D3 group, we observed viability recovery up to >80% for artificial mimic, -100% for high microRNA-21 activity cell lines and even in co-culture condition. Therefore, our method could effectively reduce the effect of leaky expression from microRNA switches.
[0071] EXAMPLE 4— THE CELL PURIFICATION METHOD CAN BE INCORPORATED INTO MRNA LOGIC GATE
[0072] In the experiment, HEK293 were seeded in 24-well plate 24 hours before transfection at 0.5 x 105cells / well. The cells were transfected with 600 nM of miR-21-ALP, miR-IDT- ALP, miR-21 / IDT-ALP or both miR-21-ALP and miR-IDT-ALP (noted as miR-21- ALP / miR-IDT-ALP). The cells were co-transfected with 2 nM microRNA mimics and 90 nM PuroR mRNA or 90 nM PuroR mRNA only for the group “w / o mimic”. At 24 hours posttransfection, peptide treatment with D-3 peptide was performed. After that, MTT based cell viability assay was performed following manufacturer’s protocol.
[0073] We constructed ALP expressing mRNA switches that sense miR-21, miR-IDT, or both (FIG. 5A) as a model decision making smart mRNA for target delivery. As shown in FIG. 5B, the cell viabilities response to each switch and the co-transfected microRNA mimic as expected. However, a drop in viability for target cell especially in miR-IDT-ALP switch group can also be observed. With the incorporation of multi-input logic circuits, more precise and criteria of cell purification can be achieved.
[0074] EXAMPLE 5— THE CELL PURIFICATION METHOD DEMONSTRATED NEURON CELLS AFTER DIFFERENTIATION
[0075] In the experiment, 201B7, Neuron and 201B7dl4 were seeded in 24-well plate 24 hours before transfection at 0.5 x 105cells / well. For co-culture experiment, differentiated neuron culture and 201B7dl4 were seeded in 6-well plate 24 hours before transfection at 1 x 105and 1 x 105cells / well respectively. The cells were transfected with 600 nM of miR-31- ALP or ALP mRNA and co-transfected with 90 nM PuroR mRNA for positively transfected cells selection. At 24 hours post-transfection, peptide treatment with D-3 peptide was performed. After that, MTT based cell viability assay was performed following manufacturer’s protocol. For co-culture experiment, the cells were either analysis by antibody staining or alkaline phosphatase staining. For antibody staining, the cells were resuspended in culture medium with trypsin and stained with anti-Nestin antibody (Abeam) and anti-OCT3 / 4 antibody Alexa Fluor 488 (Thermofisher) following standard antibody staining protocol. The result was analyzed by flow cytometry with Attune NxT (Invitrogen). For alkaline phosphatase staining, the cells were kept culturing until day 7 after peptide treatment. The alkaline phosphatase of the cells was stained by Alkaline Phosphatase stain kit (Thermofisher) following manufacturer’s protocol.
[0076] During differentiation, the cell culture would usually result in heterogeneous mixture of target cells, undifferentiated cells and incorrectly differentiated cells. Therefore, we demonstrated the purification of differentiation with our method. First, we differentiated iPSC 201B7 into neuron cells (FIG. 6A) and construct miR-31-ALP switch, where microRNA-31 is the marker microRNA for neuron cells. To represent the incorrectly differentiated cells, we differentiated the 201B7 into randomly differentiated tissue nonspecific cells, 201B7dl4. As shown in FIG. 6B, the viability of neuron remained >90% for both miR-31 ALP switch + D3 and D3 only. The undifferentiated 201B7 had high level of ALP activity as stated in the first section, was effectively removed in all condition with D3 treatment, while the randomly differentiated 201B7dl4 was only eliminated in the present of either miR-31 -ALP switch or ALP mRNA. Then, we differentiated the neuron cells, added with 201B7dl4 and purified it with our method. As shown in FIG. 6C, the treated cells successfully restored neuron population (Nestin+) from -50% to 90% while the undifferentiated population is reduced from -13% to 2%. Furthermore, we continued incubating the co-culture for a week and the undifferentiated cells were stained with ALP stain. As shown in FIG. 6D, due to the difference of growth rate, majority of control group was undifferentiated cells. For the treated group, surprisingly, no undifferentiated cells are observed. This showed that our method can successfully purify cells during differentiation.
[0077] EXAMPLE 6— THE CELL PURIFICATION METHOD CAN SENSE PROTEIN TO PURIFY CELLS
[0078] In this experiment, HEK293 were seeded in 24-well plate 24 hours before transfection at 0.5xl05cells / well. The cells were transfected with 600 nM of MS2-ALP or MS2-Bim. The cells were co-transfected with 160 nM MCP mRNA and 90 nM PuroR mRNA or PuroR mRNA only. At 24 hours post-transfection, peptide treatment with D-3 peptide was performed for cells transfected by ALP mRNA. After that, MTT based cell viability assay was performed following manufacturer’s protocol.
[0079] We constructed ALP expressing mRNA switch and Bim expressing switch that sense MCP protein. As shown in FIG. 7, the switches were transfected to HEK293 cells with or without co-transfection of MCP encoding mRNA. As shown in FIG. 7, the ALP switch with D-3 treatment recovered near 100% of the MCP expressing cells, while eliminated majority of the MCP non-expressing cells. The purification performance of our method is clearly better than the excising Bim switch method.
[0080] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and / or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.
Claims
CLAIMSWe claim:
1. A method of purifying a cell, the method comprising: i) applying to the cell an mRNA sequence encoding a cell surface alkaline phosphatase operably linked to a nucleotide sequence targeting a cytosolic cell type marker molecule or an mRNA sequence encoding the cell surface alkaline phosphatase operably linked to a nucleotide sequence targeting a viral coat protein and an mRNA sequence encoding the viral coat protein operably linked to the nucleotide sequence targeting a cytosolic cell type marker molecule; and ii) incubating the cell in a culture media.
2. The method of claim 1, wherein the culture media comprises a phosphorylated D-amino acid formed peptide with an N terminus modified with an aromatic ring.
3. The method of claim 2, wherein the phosphorylated D-amino acid formed peptide with an N terminus modified with an aromatic ring is D-l (Formula (I)), D-2 (Formula (II)), D-3 (Formula (III)), D-4 (Formula (IV)), D-5 (Formula (V)), D-6 (Formula (VI)), D-7 (Formula (VII)), or D-8 (Formula (VIII)):Formula (I)Formula (II)Formula (V)Formula (VIII)4. The method of claim 3, wherein the phosphorylated D-amino acid formed peptide with an N terminus modified with an aromatic ring is D-3 (Formula (III)): Formula (III)5. The method of claim 1, wherein the cell is a neuron.
6. The method of claim 1, wherein the cell does not express a surface alkaline phosphatase.
7. The method of claim 1, wherein the cytosolic cell type marker is microRNA- 21, microRNA-31, or microRNA-132.
8. The method of claim 1, wherein the viral coat protein is bacteriophage MS2 coat protein (MCP).
9. The method of claim 1, wherein the cell surface alkaline phosphatase sequence is separated from the sequence targeting the cytosolic cell type marker molecule or the sequence encoding the viral coat protein by 0 to about 150 nucleotides.
10. The method of claim 1, wherein the sequence targeting the cytosolic cell type marker molecule is separated from the sequence encoding the viral coat protein by 0 to about 150 nucleotides.
11. The method of claim 1, wherein the mRNA sequence encoding the cell surface alkaline phosphatase operably linked to the nucleotide sequence targeting the cytosolic cell type marker molecule is about 1600 nucleotides to about 3000 nucleotides in length.
12. The method of claim 1, wherein the mRNA sequence encoding the cell surface alkaline phosphatase operably linked to the nucleotide sequence targeting the viral coat protein is about 1600 nucleotides to about 3000 nucleotides in length.13 The method of claim 1, where the mRNA sequence encoding the viral coat protein operably linked to the nucleotide sequence targeting the cytosolic cell type marker molecule is about 400 nucleotides to about 2000 nucleotides in length.
Citation Information
Patent Citations
Method for cell-specifically controlling nuclease
US20190256830A1
HIGH EXPRESSION mRNA SWITCH
US20210079440A1
